Calcitonin gene related peptide in migraine: Current therapeutics, future implications and potential off-target effects

Jason Charles Ray*, Mahima Kapoor, Richard J. Stark, Shuu Jiun Wang, Lars Bendtsen, Manjit Matharu, Elspeth Jane Hutton

*此作品的通信作者

研究成果: Review article同行評審

16 引文 斯高帕斯(Scopus)

摘要

Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.

原文English
文章編號324674
頁(從 - 到)1325-1334
頁數10
期刊Journal of Neurology, Neurosurgery and Psychiatry
92
DOIs
出版狀態Published - 11月 2021

指紋

深入研究「Calcitonin gene related peptide in migraine: Current therapeutics, future implications and potential off-target effects」主題。共同形成了獨特的指紋。

引用此